Nupelo

Nupelo is a topical hair regrowth treatment developed by ViaDerma, Inc. The product's active ingredient is minoxidil, a small molecule vasodilator that is delivered using ViaDerma's proprietary transdermal drug delivery technology. Nupelo is intended for the treatment of hair loss, specifically targeting androgenetic alopecia. As of 2023, the product was in the final stages of the FDA registration process, though the application was placed on hold pending further regulatory updates. To navigate these hurdles, the developer has considered reformulating with natural ingredients or distributing the minoxidil-based version through compounding pharmacies.

Brand names

Nupelo